呼呼哈哈
Lv23
120 积分
2024-01-02 加入
-
Understanding the complexity of p53 in a new era of tumor suppression
3天前
已完结
-
Metastasis: from dissemination to organ-specific colonization
5天前
已完结
-
A renaissance for SRC
5天前
已完结
-
ARID1A suppresses R-loop mediated STING-Type I Interferon pathway activation of anti-tumor immunity
8天前
已完结
-
The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis
9天前
已完结
-
Genetic interactions reveal distinct biological and therapeutic implications in breast cancer
20天前
已完结
-
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial
1个月前
已完结
-
Genetic interactions reveal distinct biological and therapeutic implications in breast cancer
1个月前
已完结
-
Pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression in patients with HER2-positive metastatic breast cancer (MBC) - The PERNETTA trial (SAKK 22/10), a randomized open label phase II study (SAKK, UNICANCER, BOOG)
1个月前
已关闭
-
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial
1个月前
已完结